Aarti Drugs Limited

Aarti Drugs Limited

504.15
INR
+2.35
(+0.47%)
25.06EPS
17.17P/E
39.30BMarket Cap
Jan 27Next Earn

Total Valuation

INR

As of September 30, 2026, Aarti Drugs Limited carries a market capitalization of 39.30B, placing it among publicly traded companies globally. Its enterprise value stands at 45.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap39.30B
Enterprise Value45.24B

Important Dates

Aarti Drugs Limited's next confirmed earnings release is scheduled for January 27, 2027.

Earnings Date1/27/2027

Share Statistics

As of September 30, 2026, Aarti Drugs Limited has 91.27M shares outstanding.

Shares Outstanding91.27M

Valuation Ratios

As of September 30, 2026, Aarti Drugs Limited trades at a trailing price-to-earnings ratio of 17.17. The price-to-sales ratio is 1.38, and the price-to-book ratio stands at 2.34.

PE Ratio17.17
PS Ratio1.38
PB Ratio2.34
P/TBV Ratio2.36

Enterprise Valuation

As of September 30, 2026, Aarti Drugs Limited trades at an EV/EBITDA multiple of 11.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 45.24B versus a market cap of 39.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.59
EV / EBITDA11.83
EV / EBIT14.65

Financial Position

As of September 30, 2026, Aarti Drugs Limited maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.84, indicating elevated leverage, while an interest coverage ratio of 10.53 demonstrates strong ability to service its debt obligations.

Current Ratio1.59
Quick Ratio0.02
Debt / Equity36.84
Debt / EBITDA1.62
Interest Coverage10.53

Financial Efficiency

INR

Over the twelve months ended September 30, 2026, Aarti Drugs Limited posted a return on equity (ROE) of 14.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.08, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.92, useful for judging operating efficiency across full business cycles. The company generates approximately 10.04M in revenue per employee across its workforce of 2,839.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.29 indicates how many times Aarti Drugs Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)14.53
Return on Assets (ROA)8.08
Return on Invested Capital (ROIC)11.65
Return on Capital Employed (ROCE)11.92
Revenue Per Employee10.04M
Employee Count2,839.50
Inventory Turnover3.29

Taxes

INR

Over the twelve months ended September 30, 2026, Aarti Drugs Limited recorded 491.90M in income tax expense. That works out to an effective tax rate of 17.70, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.78B, leaving 2.29B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax491.90M
Effective Tax Rate17.70

Stock Price Statistics

INR

As of the close on November 17, 2026, Aarti Drugs Limited's stock has gained approximately 8.90% over the past 52 weeks. The 50-day moving average sits at 432.96, while the 200-day moving average is 394.94.

52-Week Price Change8.90%
50-Day Moving Average432.96
200-Day Moving Average394.94

Income Statement

INR

Over the twelve months ended September 30, 2026, Aarti Drugs Limited generated 28.51B in revenue and converted that into 2.29B in net income, yielding earnings per share of 25.06. EBITDA reached 3.82B, while operating income came in at 3.11B.

Revenue28.51B
Gross Profit10.87B
Operating Income3.11B
Pretax Income2.78B
Net Income2.29B
EBITDA3.82B
EBIT3.09B
Earnings Per Share (EPS)25.06

Balance Sheet

INR

As of September 30, 2026, Aarti Drugs Limited holds 257.60M in cash and equivalents against 6.20B in total debt, resulting in a net debt position of 6.10B. Total book value stands at 16.82B, with working capital of 6.14B providing operational flexibility.

Cash & Cash Equivalents257.60M
Total Debt6.20B
Net Debt6.10B
Equity (Book Value)16.82B
Book Value Per Share184.24
Working Capital6.14B

Margins

Over the twelve months ended September 30, 2026, Aarti Drugs Limited posted a gross margin of 38.14, reflecting its pricing power and cost economics. The operating margin of 10.91 and net profit margin of 8.03 provide insight into operational efficiency.

Gross Margin38.14
Operating Margin10.91
Pretax Margin9.75
Profit Margin8.03
EBITDA Margin13.41

Stock Splits

Aarti Drugs Limited's most recent stock split took place on September 30, 2020 with a 1:4 split ratio.

Last Split Date9/30/2020
Split Ratio1:4